In this article NOV.N-CH NVS LLY BMY AZN-GB Follow your favorite stocks CREATE FREE ACCOUNT Skynesher | E+ | Getty Images Big pharma is betting billions on an up-and-coming class of cancer treatments that some on Wall Street are calling a "massive opportunity." It's called targeted radiopharmaceutical therapy.
It essentially delivers radiation directly into tumors by attaching a radioactive particle to a targeting molecule. RBC Capital Markets sees a $25 billion market opportunity for the space. "We believe TRT development is still in its early stages, and next-generation technologies that enable improvements in therapeutic potency and address a wider range of cancer targets have the potential to drive value creation in the space," analyst Gregory Renza, M.
D., wrote in a February note. Four acquisitions in the space were announced in just the last several months.
The latest was by Novartis, which already has two targeted radiotherapies on the market. Pluvicto treats a certain type of advanced prostate cancer, while Lutathera targets neuroendocrine tumors. Pluvicto, which faced some now-resolved supply constraints in 2023, is nearing blockbuster status, bringing in $980 million in sales in 2023.
By 2028, the two drugs combined are expected to generate $5 billion in revenue, Renza said. Stock Chart Icon Stock chart icon Novartis' one-year performance A market leader with 'an aggressive strategy' Earlier this month, Novartis said it entered into an agreement to acquire Mariana O.
